We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$39.3B
1-Year Est. Return
27.96%
This Fund
S&P 500
This Quarter
Est. Return
+13.03%
1 Year Est. Return
+27.96%
3 Year Est. Return
+58.37%
5 Year Est. Return
+80.22%
10 Year Est. Return
+439.89%
AUM
$39.3B
AUM Growth
+$3.7B
(+10%)
Cap. Flow
+$2.27B
Cap. Flow
% of AUM
5.78%
Top 10 Holdings %
Top 10 Hldgs %
11.24%
Holding
2,749
New
386
Increased
1,048
Reduced
996
Closed
125
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lowe's Companies
LOW
|
+$393M |
| 2 |
AngloGold Ashanti
AU
|
+$356M |
| 3 |
General Dynamics
GD
|
+$348M |
| 4 |
NVIDIA
NVDA
|
+$202M |
| 5 |
Kroger
KR
|
+$198M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$441M |
| 2 |
CVS Health
CVS
|
+$424M |
| 3 |
United Parcel Service
UPS
|
+$359M |
| 4 |
Devon Energy
DVN
|
+$243M |
| 5 |
Target
TGT
|
+$194M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.71% |
| 2 | Miscellaneous | 16.91% |
| 3 | Healthcare | 12.7% |
| 4 | Consumer Discretionary | 10.42% |
| 5 | Communication Services | 7.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
TG Therapeutics
TGTX
$8.57B
| $54K | ﹤0.01% |
+989
| New | +$40.5K |
|
1252
Madrigal Pharmaceuticals
MDGL
$12.5B
| $53K | ﹤0.01% |
+98
| New | +$50.2K |
|
1253
Protagonist Therapeutics
PTGX
$9.43B
| $53K | ﹤0.01% |
436
-4,480
| -91% | -$468K |
|
1254
Vera Therapeutics
VERA
$2.59B
| $53K | ﹤0.01% |
+1,227
| New | +$45.7K |
|
1255
BridgeBio Pharma
BBIO
$14.6B
| $51K | ﹤0.01% |
+684
| New | +$47.9K |
|
1256
CRISPR Therapeutics
CRSP
$5.39B
| $51K | ﹤0.01% |
+932
| New | +$49.1K |
|
1257
ImmunityBio
IBRX
$8.56B
| $51K | ﹤0.01% |
+5,786
| New | +$43.8K |
|
1258
PTC Therapeutics
PTCT
$5.78B
| $51K | ﹤0.01% |
+629
| New | +$45.4K |
|
1259
uniQure
QURE
$3.09B
| $51K | ﹤0.01% |
+1,110
| New | +$29.1K |
|
1260
Ionis Pharmaceuticals
IONS
$9.65B
| $50K | ﹤0.01% |
+629
| New | +$47.3K |
|
1261
Summit Therapeutics
SMMT
$14B
| $50K | ﹤0.01% |
+3,451
| New | +$61.2K |
|
1262
Acadia Pharmaceuticals
ACAD
$4.83B
| $47K | ﹤0.01% |
+1,841
| New | +$40.5K |
|
1263
Immunovant
IMVT
$8.11B
| $46K | ﹤0.01% |
+1,193
| New | +$36.3K |
|
|
NUVL
1264
DELISTED
Nuvalent
NUVL
| $46K | ﹤0.01% |
+374
| New | +$40.2K |
|
1265
Intellia Therapeutics
NTLA
$1.79B
| $45K | ﹤0.01% |
+2,665
| New | +$37.3K |
|
|
GRAL
1266
GRAIL Inc
GRAL
$3.59B
| $45K | ﹤0.01% |
+660
| New | +$38.9K |
|
1267
BioCryst Pharmaceuticals
BCRX
$2.55B
| $44K | ﹤0.01% |
4,436
-1,558,604
| -100% | -$14.1M |
|
1268
Futu Holdings
FUTU
$17.1B
| $44K | ﹤0.01% |
466
-20
| -4% | -$2.56K |
|
|
CPRX
1269
DELISTED
Catalyst Pharmaceutical
CPRX
| $43K | ﹤0.01% |
1,382
-360,412
| -100% | -$10.6M |
|
1270
Dyne Therapeutics
DYN
$4.53B
| $43K | ﹤0.01% |
+1,922
| New | +$35.7K |
|
1271
MarketAxess Holdings
MKTX
$5.75B
| $43K | ﹤0.01% |
377
-67
| -15% | -$9.55K |
|
1272
Tango Therapeutics
TNGX
$3.8B
| $42K | ﹤0.01% |
+1,338
| New | +$33.1K |
|
1273
Denali Therapeutics
DNLI
$3.56B
| $41K | ﹤0.01% |
+1,609
| New | +$33.1K |
|
1274
IDEAYA Biosciences
IDYA
$3.85B
| $40K | ﹤0.01% |
+1,071
| New | +$32.8K |
|
1275
Amer Sports
AS
$17.2B
| $40K | ﹤0.01% |
1,195
-55
| -4% | -$1.93K |
|
Similar funds
PPF
CS
Pacer Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Pacer Advisors held 2,749 positions worth $39.3B, up 10% from $35.6B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Pacer Advisors deployed $2.27B of net new capital in Q2 2026, opening 386 new positions and adding to 1,048 existing holdings. Its largest new stake was AngloGold Ashanti: 3,744,168 shares worth $303M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Miscellaneous and Healthcare.
On the sell side, the largest reduction was ConocoPhillips, an estimated $441M trimmed.
- Pacer Advisors's largest Q2 2026 buy was AngloGold Ashanti: 3,744,168 shares worth $303M.
- Pacer Advisors added most to Lowe's Companies in Q2 2026, an estimated $393M increase.
- Pacer Advisors's biggest Q2 2026 reduction was ConocoPhillips, cutting an estimated $441M.
- Pacer Advisors fully exited Coterra Energy in Q2 2026, selling an estimated $118M.
- Pacer Advisors's ten largest holdings make up 11% of its $39.3B portfolio in Q2 2026.
- Pacer Advisors opened 386 new positions and closed 125 in Q2 2026.
- Pacer Advisors's portfolio value rose 10% quarter-over-quarter to $39.3B.
Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.